Key Developments: Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

175.42USD
27 Mar 2015
Change (% chg)

$2.03 (+1.17%)
Prev Close
$173.39
Open
$173.57
Day's High
$177.45
Day's Low
$173.57
Volume
165,657
Avg. Vol
196,891
52-wk High
$190.00
52-wk Low
$120.38

Search Stocks

Latest Key Developments (Source: Significant Developments)

Jazz Pharmaceuticals PLC completes sale of certain products that company originally acquired as part of company’s acquisition of EUSA Pharma Inc and business related thereto - Form 8-K
Monday, 23 Mar 2015 09:11am EDT 

Jazz Pharmaceuticals PLC:As previously disclosed, company entered into an agreement in the fourth quarter of 2014 to sell certain products that company originally acquired as part of Company’s acquisition of EUSA Pharma Inc. and business related thereto to Essex Bidco Limited, a company controlled by Essex Woodlands.On March 20, the Company completed the sale of the Disposed Business pursuant to the Sale Agreement.Pursuant to the Sale Agreement, the purchase price for the Disposed Business was $34 mln, subject to certain adjustments.As of the closing, the Company was entitled to receive about $33 mln in cash after purchase price adjustments were made prior to the closing.Purchase price is subject to potential further adjustments post-closing.Products in the Disposed Business sold to Essex included Caphosol (supersaturated calcium phosphate rinse), Collatamp (lyophilized collagen implant impregnated with the aminoglycoside antibiotic gentamicin), Fomepizole (fomepizole), Xenazine (tetrabenazine) and Custodiol.  Full Article

Jazz Pharmaceuticals PLC gives FY 2015 guidance below analysts' estimates
Tuesday, 24 Feb 2015 04:05pm EST 

Jazz Pharmaceuticals PLC:Expects FY 2015 revenues of $1.310-$1.370 billion.Expects FY 2015 GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share of $5.17-$5.70.Expects FY 2015 Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share of $9.45-$9.75.FY 2015 revenue of $1.40 billion and EPS of $10.11 - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC raises FY 2014 guidance
Tuesday, 4 Nov 2014 04:05pm EST 

Jazz Pharmaceuticals PLC:Expect FY 2014 revenues of $1.150-$1.170 billion.FY 2014 GAAP net income per diluted share of $0.73-$1.05.FY 2014 Non-GAAP Adjusted Net Income Per Diluted Share of $8.20-$8.35.FY 2014 revenue of $1.158 billion and EPS of $8.18 - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC announces pricing of $500 mln of exchangeable senior notes
Friday, 8 Aug 2014 06:30am EDT 

Jazz Pharmaceuticals PLC:Offering of $500 mln aggregate principal amount of exchangeable senior notes due 2021.Issuer has also granted initial purchasers of notes 30-day option to purchase up to an additional $75 mln aggregate principal amount of notes from Issuer solely to cover over-allotments, if any.Interest on notes will be payable semi-annually in cash in arrears on Feb. 15 and Aug. 15 of each year, beginning on Feb. 15, 2015 at rate of 1.875 pct per year.Says notes will mature on Aug. 15, 2021, unless earlier exchanged, repurchased or redeemed.Sale of notes is expected to close on Aug. 13, 2014, subject to customary closing conditions.Use portion of net proceeds to repay outstanding borrowings under its revolving credit facility and to use remainder of net proceeds for general corporate purposes, including potential business development activities.  Full Article

Jazz Pharmaceuticals PLC announces proposed offering of $500 million of exchangeable senior notes
Wednesday, 6 Aug 2014 04:06pm EDT 

Jazz Pharmaceuticals PLC:Says Jazz Investments I Limited, its wholly-owned subsidiary (Issuer), intends to offer, $500 mln aggregate principal amount of exchangeable senior notes due 2021 in private offering to qualified institutional buyers.In connection with offering, Issuer expects to grant initial purchasers an option to purchase up to additional $75 mln aggregate principal amount of such notes solely to cover over-allotments, if any.Notes will be exchangeable under certain circumstances for cash, ordinary shares of Jazz Pharmaceuticals plc or a combination thereof, based on exchange rate to be determined.Issuer's obligations under notes will be fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc.Initial exchange rate, interest rate and certain other terms of notes will be determined by negotiations between Jazz Pharmaceuticals and the initial purchasers.Jazz Pharmaceuticals intends to use portion of net proceeds from proposed offering to repay outstanding borrowings under revolving credit facility and to use remainder of the net proceeds for general corporate purposes, including potential business development activities.  Full Article

Jazz Pharmaceuticals PLC raises FY 2014 revenue guidance; reaffirms FY 2014 EPS guidance
Tuesday, 5 Aug 2014 04:05pm EDT 

Jazz Pharmaceuticals PLC:Expect FY 2014 revenues of $1.125-$1.165 bln (prior range of $1.100-$1.160 bln).FY 2014 GAAP net income per diluted share of $0.47-$0.90.FY 2014 Non-GAAP Adjusted Net Income Per Diluted Share of $8.00-$8.25.FY 2014 revenue of $1.132 bln and EPS of $8.07 - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC completes acquisition of rights to defibrotide in the Americas from Sigma-Tau Pharmaceuticals, Inc.
Tuesday, 5 Aug 2014 04:01pm EDT 

Jazz Pharmaceuticals PLC:Announced the closing of its acquisition of rights to defibrotide in the United States (U.S.) and all other countries in the Americas from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau).Under the previously-announced definitive agreement with Sigma-Tau, a wholly-owned subsidiary of Jazz Pharmaceuticals acquired the rights to defibrotide in the Americas.For an upfront payment of $75 million plus potential milestone payments of $25 million upon the acceptance for filing by the FDA of the first NDA for defibrotide for VOD.  Full Article

CANbridge Life Sciences and Jazz Pharmaceuticals PLC's EUSA Pharma form agreement to commercialize Caphosol in China
Monday, 28 Jul 2014 11:34am EDT 

Jazz Pharmaceuticals PLC:Says CANbridge Life Sciences enters into exclusive partnership with EUSA Pharma, Jazz Pharmaceuticals company, to commercialize Caphosol in China.Under terms of agreement, CANbridge obtains exclusive rights to commercialize Caphosol in China, where over 3.5 mln new cancer cases are diagnosed each year, and there is little in way of standard adjunct therapy to treat oral mucositis.  Full Article

Jazz Pharmaceuticals PLC and Concert Pharmaceuticals provide a Phase 1 clinical trial update on JZP-386
Monday, 21 Jul 2014 04:00pm EDT 

Jazz Pharmaceuticals PLC and Concert Pharmaceuticals:Says initiation of first Phase 1 clinical trial of JZP-386, deuterium-containing analog of sodium oxybate_the active ingredient in Xyrem (sodium oxybate) oral solution.Phase 1 clinical trial is designed to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JZP-386, and includes Xyrem as an active control.Study is expected to enroll up to 28 healthy subjects at single center in Europe.Results of the study are intended to assess PK/PD profile of JZP-386 to identify safe and tolerable dose or doses of JZP-386 that could be used in subsequent clinical trials and to determine whether JZP-386 is suitable for once nightly dosing.  Full Article

Jazz Pharmaceuticals PLC's subsidiary to acquire rights to Defibrotide In Americas From Sigma-Tau Pharmaceuticals, Inc.
Wednesday, 2 Jul 2014 08:00am EDT 

Jazz Pharmaceuticals PLC:Signs definitive agreement with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) under which subsidiary of Jazz Pharmaceuticals plc (Jazz) will acquire from Sigma-Tau rights to defibrotide in United States (U.S.) and all other countries in the Americas.Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year.Sigma-Tau would receive an upfront payment of $75 mln upon closing of the transaction.Sigma-Tau would be eligible to receive milestone payments of $25 mln upon the acceptance for filing by FDA of first NDA for defibrotide for VOD and up to an additional $150 mln based on the timing of potential FDA approval of defibrotide for VOD.  Full Article

Search Stocks